Alnylam Pharmaceuticals, Inc. Cambridge, MA United States
Company Description
Call it The Silence of the Genes. Alnylam Pharmaceuticals runs interference with RNA to prevent disease. RNA interference (RNAi) technology developed by the biotech firm can selectively shut off harmful genes. The company is developing a pipeline of candidates both individually and through collaborations with other drugmakers. Its disease targets include rare genetic disorder ATTR (transthyretin-mediated amyloidosis) and RSV (respiratory syncytial virus), a common childhood viral infection. Additional R&D programs target neurological disorders, cardiovascular conditions, and cancers. Alnylam has R&D alliances and licensing agreements with companies including
| 300 3rd St., 3rd Fl. | Phone: 617-551-8200 | |
| Cambridge, MA 02142 | Fax: 617-551-8101 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Alnylam Pharmaceuticals, Inc. Rankings
| Russell 2000 (June 2011) |
Executives
| 40 executives listed for Alnylam Pharmaceuticals, Inc. 's Cambridge, MA location. | ||
| Chairman | John Clarke | |
|---|---|---|
| CEO and Director | John Maraganore | |
| President and COO | Barry Greene | |
Financials
| Company Type | Public - NASDAQ: ALNY Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 116 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Alnylam Pharmaceuticals, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
